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lesional inflammatory cell infiltration,
vascular adhesion molecules, or angio-
genesis (Figure 2). When comparing
C-Tg with C-NT mice, we found sig-
nificantly more CD3þ cells, CD4þ
cells, and CD8þ cells in the Tg strain’s
dermis (all with Po0.001). Similarly,
the B-Tg dermis had significantly more
CD3þ cells (Po0.01), CD4þ cells
(Po0.01), and CD8þ cells (Po0.05)
compared with its B-NT counterpart.
Both C-Tg and B-Tg mice had signifi-
cantly more PECAMþ vessels per high-
power field compared with their NT
littermates (Po0.001), further support-
ing a role of angiogenesis in AD (Chen
et al., 2008a). Similarly, C-Tg and
B-Tg mice had more P-selectinþ and
VCAMþ vessels than did their NT
littermates (Po0.001); this was identi-
cal to the previous findings in AD
patients and in an AD model (Sigurds-
son et al., 2000; Chen et al., 2010).
There was no difference in numbers
of CD3þ and CD4þ lymphocytes,
PECAMþ , and P-selectinþ vessels
between the dermis of the two Tg
strains. The physiological implications
of more CD8þ cells and VCAMþ
vessels per high-power field in the
dermis but with less skin inflammation
in C-Tg mice, as compared with B-Tg
mice, are unclear (Figure 2b and c).
The Th2 systemic immune milieu
strongly enhances the rate and extent
of cutaneous inflammation in our
AD model by primarily increasing the
expression of cutaneous Th2 cytokines
and other proinflammatory cytokine.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work has been supported by the Albert H.
and Mary Jane Slepyn Endowed Fellowship,
University of Illinois College of Medicine,
Chicago, Illinois.
Marie E. Reichle1, Lin Chen2,
Shao-Xia Lin1 and Lawrence S. Chan1,3,4
1Department of Dermatology, College of
Medicine, University of Illinois at Chicago,
Chicago, Illinois, USA; 2Department of Oral
Biology, College of Dentistry, University of
Illinois at Chicago, Chicago, Illinois, USA;
3Department of Microbiology/Immunology,
College of Medicine, University of Illinois at
Chicago, Chicago, Illinois, USA and 4Medicine
Service, Jesse Brown VA Medical Center,
Chicago, Illinois, USA
E-mail: larrycha@uic.edu
REFERENCES
Bonness S, Bieber T (2007) Molecular basis of
atopic dermatitis. Curr Opin Allergy Clin
Immunol 7:382–6
Chan LS, Robinson N, Xu L (2001) Expression of
interleukin-4 in the epidermis of transgenic
mice results in a pruritic inflammatory skin
disease: an experimental animal model to study
atopic dermatitis. J Invest Dermatol 117:977–83
Chen L, Lin S-X, Amin S et al. (2010) VCAM-1
blockade delays disease onset, reduces
disease severity and inflammatory cells in an
atopic dermatitis model. Immunol Cell Biol
88:334–42
Chen L, Lin SX, Overbergh L et al. (2005b)
The disease progression in the keratin 14 IL-4-
transgenic mouse model of atopic dermatitis
parallels the up-regulation of B cell activation
molecules, proliferation and surface and serum
IgE. Clin Exp Immunol 142:21–30
Chen L, Marble DJ, Agha R et al. (2008a) The
progression of inflammation parallels the
dermal angiogenesis in a keratin 14 IL-4-
transgenic model of atopic dermatitis. Micro-
circulation 15:49–64
Chen L, Martinez O, Overbergh L et al. (2004)
Early up-regulation of Th2 cytokines and late
surge of Th1 cytokines in an atopic dermatitis
model. Clin Exp Immunol 138:375–83
Chen L, Martinez O, Venkataramani P et al.
(2005a) Correlation of disease evolution with
progressive inflammatory cell activation and
migration in the IL-4 transgenic mouse model
of atopic dermatitis. Clin Exp Immunol
139:189–201
Chen L, Overbergh L, Mathieu C et al. (2008b)
The development of atopic dermatitis is
independent of immunoglobulin E up-regula-
tion in the k14-IL-4 SKH1 mouse model.
Clin Exp Allergy 38:1367–80
Hanifin JM (2009) Evolving concepts of pathogen-
esis of atopic dermatitis and other eczemas.
J Invest Dermatol 129:320–2
Jones HE, Inouye JC, McGerity JL et al. (1975)
Atopic disease and serum immunoglobulin-E.
Br J Dermatol 92:17–25
Lee GR, Flavell RA (2004) Transgenic mice which
overproduce Th2 cytokines develop
spontaneous atopic dermatitis and asthma.
Int Immunol 16:1155–60
Lopez-Kostka S, Dinges S, Griewank K et al.
(2009) IL-17 promotes progression of cuta-
neous leishmaniasis in susceptible mice.
J Immunol 182:3039–46
Novak N, Bieber T (2003) Allergic and nonallergic
forms of atopic diseases. J Allergy Clin
Immunol 112:252–62
Sigurdsson V, de Vries IJ, Toonstra J et al. (2000)
Expression of VCAM-1, ICAM-1, E-selectin, and
P-selectin on endothelium in situ in patients
with erythroderma, mycosis fungoides and
atopic dermatitis. J Cutan Pathol 27:436–40
Yamamura M, Uyemura K, Keans RJ et al. (1991)
Defining protective responses to pathogens:
cytokine profiles in leprosy lesions. Science
254:277–9
High Levels of Soluble ST2 and Low Levels of IL-33 in
Sera of Patients with HIV Infection
Journal of Investigative Dermatology (2011) 131, 794–796; doi:10.1038/jid.2010.366; published online 9 December 2010
TO THE EDITOR
IL-33, a novel member of the IL-1
family, was recently identified as a
ligand for the orphan receptor ST2
(Schmitz et al., 2005). ST2 is selectively
and stably expressed on the cell surface
of T-helper 2 (Th2) cells, but not Th1
cells (Xu et al., 1998). IL-33–ST2 inter-
actions exacerbate Th2- and mast
cell-mediated inflammatory diseases
(Pre´fontaine et al., 2009). The soluble
form of ST2 functions as a decoyAbbreviations: AD, atopic dermatitis; Th, T helper
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receptor, which neutralizes IL-33 and
acts as a negative regulator of Th2
cytokine production by IL-33 signaling
(Hayakawa et al., 2007). Although
IL-33 was highly expressed in lesional
skin of atopic dermatitis (AD), serum
IL-33 levels in AD patients were not
increased (Pushparaj et al., 2009). On
the other hand, serum soluble ST2
levels are elevated in patients with
asthma (Oshikawa et al., 2001). IL-33
is important in the lesion sites in Th2
type immune responses, while soluble
ST2 seems to be a more sensitive serum
marker for Th2 diseases. IL-33 also has
important roles in host protection
against infections (Humphreys et al.,
2008; Alves-Filho et al., 2010;
Jones et al., 2010) and prevention of
atherosclerosis (Sanada et al., 2007).
Patients with HIV infection exhibit a
wide range of skin pathology, including
bacterial, fungal, and viral infections,
skin tumors, inflammatory and eczema-
tous eruptions, and drug rashes (Spira
et al., 1998). HIV-infected adults com-
monly develop a condition that strongly
resembles AD. Elevated IgE levels, eosi-
nophilia, and increased Th2 activity are
reported in patients with HIV infection
(Rudikoff, 2002). In this study, we
measured soluble ST2 and IL-33 levels
in sera of patients with HIV infection
or AD.
Twenty-six patients with HIV infec-
tion (mean±SD age: 43.8±11.3 years),
28 patients with AD and without HIV
infection (28.5±8.1 years), and 21
healthy control subjects (39.9±19.1
years) were enrolled in this study. Eight
of 26 patients with HIV infection had
HIV-related eosinophilic folliculitis,
four had pruritic papular eruptions,
six had tinea pedis, and others had
syphilis, herpes simplex, condyloma
acuminate, or molluscum contagiosum.
All the patients except one were receiv-
ing highly active antiretroviral therapy.
The numbers of CD4þ T cells were
32–757 per ml (median¼288). The HIV
viral loads of six patients ranged
from 102.80 to 105.81 copies per ml
(median¼ 105.04). The viral loads of the
other 20 patients were o50 copies
per ml. The 21 healthy controls had
no history of allergy or any skin
diseases. Serum samples were obtained
with informed consent. The medical
ethical committee of the University of
Tokyo and the National Center for
Global Health and Medicine approved
all described studies, and the study was
conducted according to the Declaration
of Helsinki Principles. Immunoreactive
soluble ST2 and IL-33 in sera were
quantified by a human ST2/IL-1 R4
Quantikine ELISA Kit and a human
IL-33 DuoSet (R&D systems, Minnea-
polis, MN), respectively. Both kits
recognized the free form of soluble
ST2 or IL-33 and IL-33/ST2 complex.
Statistical analysis between two
groups was performed using Mann–
Whitney’s U-test. Correlation coeffi-
cients were determined by using Spear-
man’s rank correlation test. P-values
o0.05 were considered statistically
significant.
Serum soluble ST2 levels in patients
with HIV infection were 18,637.8±
10,267.7 pgml1 (mean±SD), which
were significantly higher than those
of healthy controls (11,650.1±
9,558.4 pgml1; Po0.01; Figure 1).
Serum soluble ST2 levels in patients
with AD (18,850.5±9,636.8 pgml1)
were also significantly higher than
those of healthy controls (Po0.01;
Figure 1). Serum IL-33 levels in
patients with HIV infection were 53.1±
134.8 pgml1. They were significantly
lower than those of healthy cont-
rols (355.5±439.1 pgml1; Po0.05;
Figure 2). Serum IL-33 levels in patients
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Figure 1. Serum levels of soluble ST2 in patients with HIV infection or atopic dermatitis (AD) and
in healthy controls. The measured values from individual patients are plotted with dots. The horizontal
lines represent the mean of each group. **Po0.01 by Mann–Whitney U-test.
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Figure 2. Serum IL-33 levels in patients with HIV infection or atopic dermatitis (AD) and in healthy
controls. The measured values from individual patients are plotted with dots. The horizontal lines
represent the mean of each group. *Po0.05 by Mann–Whitney U-test.
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with AD were 330.6±440.3 pgml1
(Figure 2), which were not significantly
different from healthy controls. Serum
soluble ST2 and IL-33 levels did
not correlate with age, number of
eosinophils, or other clinical and la-
boratory data. Serum IL-33 levels of
HIV patients with o250 CD4þ T cells
counts were 31.9±82.6 pgml1 and
those with 4250 CD4þ T cells counts
were 77.2±145.8 pgml1. Serum IL-33
levels of patients with a viral load of
450 copies were 10.7±9.8pgml1 and
those with a viral load of o50 copies
were 68.7±152.1pgml1. Although the
differences were not statistically signifi-
cant, there was a tendency for serum IL-
33 levels to decrease with the severity of
HIV infection.
We have shown that serum soluble
ST2 levels are elevated in patients with
HIV infection as well as AD, which may
reflect a Th2 dominant status, as seen in
patients with asthma (Oshikawa et al.,
2001). Serum IL-33 levels in patients
with AD are comparable with those in
healthy controls, which is consistent
with the previous report (Pushparaj
et al., 2009). Surprisingly, serum IL-33
levels in patients with HIV infection are
significantly lower than those of healthy
controls. There are emerging data sug-
gesting that IL-33 has key roles in host
immunity against various infections
such as bacteria, Toxoplasma gondii,
or intestinal nematodes (Humphreys
et al., 2008; Alves-Filho et al., 2010;
Jones et al., 2010). Soluble ST2 plasma
concentrations predicted mortality in
severe sepsis (Hoogerwerf et al., 2010).
Besides a decrease in CD4þ T cells,
high levels of soluble ST2 and low
levels of IL-33 in sera in patients with
HIV may contribute to high risks of
opportunistic infections. As IL-33
is reported to reduce the development
of atherosclerosis (Miller et al., 2008),
low levels of IL-33 may also
explain the high risk of atherosclerosis
in patients with HIV (Currier et al.,
2008).
In summary, this is early evidence of
high levels of soluble ST2 and low
levels of IL-33 in sera of patients with
HIV. Although more detailed study is
necessary to know the regulations of
serum levels of soluble ST2 and IL-33,
our study has revealed a new aspect of
immune impairment in HIV infection,
which may contribute to high risks of
opportunistic infections and athero-
sclerosis.
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